Madrigal Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Madrigal Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 92% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 92% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 92% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-85.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 80% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-186.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 92% of Healthcare companies in United States.
Cash Cushion Ratio
+6%Cash, after subtracting all debt, equals 6% of its market value (net cash).
Lower than 56% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 92% of Healthcare companies in United States.
Tangible Net Worth Ratio
99%Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 92% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Madrigal Pharmaceuticals, Inc. made a loss over the last year. Madrigal Pharmaceuticals, Inc. owes $0.58 for every $1 it owns. Madrigal Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMadrigal Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
20.00The share price is 20.00 times Madrigal Pharmaceuticals, Inc.'s book value per share, higher than 94% of Healthcare companies in United States.
Market cap
$10.5 BThe total market value of all of Madrigal Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 90% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$524 MWhat Madrigal Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$22.67Net worth divided by the number of shares. The share price of $453.34 is 20.0 times this, which is the P/B above.
Return on equity (ROE)
-53.3%Madrigal Pharmaceuticals, Inc. lost 53.3% of its shareholders' money over the last year, lower than 53% of Healthcare companies in United States.
Owes vs Owns
0.58×Madrigal Pharmaceuticals, Inc. owes $0.58 for every $1 it owns (moderate), higher than 62% of Healthcare companies in United States.
Dividend yield
NoneMadrigal Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+432%Revenue rose 432% in the year to Dec 2025.
Profit growth
LossMadrigal Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-30.1%Madrigal Pharmaceuticals, Inc. lost $30 for every $100 of revenue.
Interest cover
Not coveredMadrigal Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashMadrigal Pharmaceuticals, Inc. held $636 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Madrigal Pharmaceuticals, Inc.: $10.5 B ÷ $524 M (30 Jun 2026) = 20.0.
What is Madrigal Pharmaceuticals, Inc.'s return on equity?
Madrigal Pharmaceuticals, Inc. lost 53.3% of its shareholders' money over the last year, lower than 53% of Healthcare companies in United States.
How much does Madrigal Pharmaceuticals, Inc. owe compared with what it owns?
Madrigal Pharmaceuticals, Inc. owes $0.58 for every $1 it owns (moderate), higher than 62% of Healthcare companies in United States.
Does Madrigal Pharmaceuticals, Inc. pay a dividend?
No. Madrigal Pharmaceuticals, Inc. does not currently pay a dividend.
Is Madrigal Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 432% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.